- Home
- Media centre
- News features
- Andrew Witty interview on CNBC
Andrew Witty interview on CNBC
In an interview with CNBC-TV's "Power Lunch" programme on Tuesday 22 June, CEO Andrew Witty highlighted GSK’s number one ranking on the 2010 Access to Medicines Index, which evaluated the top 20 R&D-based and seven generics companies on their contribution to improving access to medicines against seven criteria:
- Access to medicine management;
- Public policy and market influence;
- R&D; Equitable pricing, manufacturing and distribution;
- Patents and licensing;
- Capability advancement in product development and distribution; and
- Product donations and philanthropy.
He discussed the importance of striking a balance between developing our business around the world in Western markets and emerging economies. He also highlighted the importance of focusing on those who do not have the economic means to access healthcare systems.
Andrew also discussed the diversification of GSK’s business, the impact of health reform, and pricing in the US versus the rest of the world.
